Factors Associated With Decision Making In the Second-Line Treatment of Patients With Advanced/Metastatic Gastrointestinal Cancers
Podcast 1: Managing GEJ Cancers in the community setting
Post-Test/Evaluation

Questions marked with a * are required

18%

Contact Information

First Name

Last Name

Email Address

Credentials/Degree (MD, DO, RN, etc.)

Date of Participation

Christine is a 68 year-old woman who presents with a mass at GE junction and diffuse liver metastases, who is started on first-line therapy. At her 3 month visit, she is noted to have progression of her metastases, and you start the discussion of second-line therapy options with her. Which of the following statements are true?

A. Combining chemotherapy with anti-VEGF agents may increase response rates and improve survival in second-line treatment

B. Trials show second-line therapy may improve overall survival and QoL when compared with basic supportive care

C. Molecular characteristics of the tumors play an important role in second-line therapeutic option choice

D. All of the above

In order to maximize Christine’s outcome, you recommend FOLFIRI/ramucirumab as her second-line therapy. What do you tell her with regard to clinical practice guidelines?

A. Involving a multidisciplinary care team plays no role in second-line therapy

B. Hypertension is one of the most common side effects of ramucirumab

C. Immunotherapy does not play a role in second-line treatment

D. None of the above